Patents Assigned to Eutropics Pharmaceuticals, Inc.
-
Patent number: 11656230Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies to detect the presence of heterodimers in the cell, as well as to determine the relationship between the antibody binding to the heterodimer in the cancer cell and the sensitivity of the cell to cancer treatment. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.Type: GrantFiled: June 25, 2020Date of Patent: May 23, 2023Assignee: Eutropics Pharmaceuticals, Inc.Inventor: Michael H. Cardone
-
Patent number: 10793915Abstract: The present disclosure provides diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.Type: GrantFiled: January 12, 2016Date of Patent: October 6, 2020Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Elisha J. Dettman, Michael H. Cardone
-
Patent number: 10765673Abstract: The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: April 2, 2018Date of Patent: September 8, 2020Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, David J. Richard
-
Patent number: 10732182Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein, or a caspase and an inhibitor of caspase-IAP heterodimer protein in the cell. The methods provide a predictive tool to identify patients likely to respond to drugs that perturb heterodimer binding and induce apoptosis in a cancer cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.Type: GrantFiled: August 1, 2014Date of Patent: August 4, 2020Assignee: Eutropics Pharmaceuticals, Inc.Inventor: Michael H. Cardone
-
Patent number: 10640803Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.Type: GrantFiled: October 30, 2014Date of Patent: May 5, 2020Assignee: Eutropics Pharmaceuticals, Inc.Inventors: William E. Pierceall, Michael H. Cardone
-
Patent number: 10413549Abstract: The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: October 24, 2017Date of Patent: September 17, 2019Assignee: Eutropics Pharmaceuticals, Inc.Inventors: David Richard, Michael H. Cardone
-
Patent number: 9360473Abstract: The invention is an assay designed to identify agents that modulate apoptosis. The invention provides an assay system and methods for screening for inhibitors of the Bcl-2 family of proteins. In various aspects the invention provides an assay system containing a liposome reagent and an immobilized BH3 domain peptide. In further aspects the invention provides an assay system containing mitochondria, an immobilized BH3 domain peptide and a mitochondrial binding agent, e.g. an anti-VDAC anti-body.Type: GrantFiled: August 16, 2007Date of Patent: June 7, 2016Assignee: EUTROPICS PHARMACEUTICALS, INC.Inventor: Michael H. Cardone
-
Patent number: 9351971Abstract: The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: February 17, 2015Date of Patent: May 31, 2016Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
-
Patent number: 9345700Abstract: The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: April 30, 2015Date of Patent: May 24, 2016Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Andrew F. Kolodziej, David Richard
-
Patent number: 9051305Abstract: The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: March 8, 2012Date of Patent: June 9, 2015Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Andrew F. Kolodziej, David Richard
-
Patent number: 8987271Abstract: The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapies, for example, 26S proteosome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: GrantFiled: December 22, 2011Date of Patent: March 24, 2015Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
-
Publication number: 20140234867Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Anthony G. Letai
-
Publication number: 20140221387Abstract: The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.Type: ApplicationFiled: March 8, 2012Publication date: August 7, 2014Applicant: EUTROPICS PHARMACEUTICALS, INC.Inventors: Michael H. Cardone, Andrew F. Kolodziej, David Richard
-
Publication number: 20120225851Abstract: The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia?, Ib?, Ic?, or II? (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia?, Ib?, Ic?, or II?.Type: ApplicationFiled: December 22, 2011Publication date: September 6, 2012Applicant: EUTROPICS PHARMACEUTICALS, INC.Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
-
Publication number: 20120225794Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: ApplicationFiled: March 23, 2012Publication date: September 6, 2012Applicant: EUTROPICS PHARMACEUTICALS, INC.Inventors: Michael H. CARDONE, Anthony G. LETAI
-
Patent number: 8168755Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: GrantFiled: May 7, 2009Date of Patent: May 1, 2012Assignee: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Anthony G. Letai
-
Publication number: 20090280510Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: ApplicationFiled: May 7, 2009Publication date: November 12, 2009Applicant: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Anthony G. Letai